Physician profile
Andy Michael Foo
NPI 1306556329
$459.43
in general payments reported to CMS, 2019-2025
15 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.27 · 2024: $284 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $70.89 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $54.89 | 2024-2025 | Airsupra |
| Abbvie INC. | $45.22 | 2024 | |
| Exact Sciences Corporation | $33.62 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $33.31 | 2023-2024 | Shingrix, Arexvy |
| Medtronic, INC. | $31.17 | 2025 | Minimed 780g |
| Depuy Synthes Sales INC. | $25.08 | 2023 | Dynacord |
| Renalytix Ai, INC. | $23.78 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $23.77 | 2024 | Mounjaro |
| Shield Therapeutics INC | $22.82 | 2024 | |
| Astellas Pharma US INC | $22.73 | 2024 | Veozah |
| Linvatec Corporation | $20.85 | 2025 | Biobrace 23mm |
| Eisai INC. | $18.56 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.06 | 2024 | Ofev |
| Amgen INC. | $14.68 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Foo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.